Sionna Therapeutics, Inc. (SION)

Market Cap	1.80B
Revenue (ttm)	n/a
Net Income (ttm)	-70.68M
Shares Out	44.63M
EPS (ttm)	-2.36
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	209,121
Open	41.05
Previous Close	40.88
Day's Range	39.75 - 42.02
52-Week Range	7.26 - 45.00
Beta	n/a
Analysts	Strong Buy
Price Target	39.17 (-2.78%)
Earnings Date	Nov 5, 2025

About SION

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 7, 2025
• Employees: 41
• Stock Exchange: NASDAQ
• Ticker Symbol: SION
• Website: https://www.sionnatx.com

Analyst Forecast

According to 6 analysts, the average rating for SION stock is "Strong Buy." The 12-month stock price target is $39.17, which is a decrease of -2.78% from the latest price.

Price Target

$39.17

(-2.78% downside)

Analyst Consensus: Strong Buy